BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Despite a challenging 2022 for Gene Therapy developers targeti
 ng the CNS\, the recent approvals of Skysona by bluebird bio and Upstaza 
 by PTC Therapeutics have validated the potential that gene therapies can 
 act as transformative medicines within the CNS community.\n\nThe 5th Gene
  Therapy for Neurological Disorders Summit is your comprehensive 4-day ev
 ent to stay ahead of cutting-edge developments\, overcome delivery challe
 nges\, address translational bottlenecks\, and create a bulletproof clini
 cal development strategy\, to propel the next wave of CNS gene therapies 
 forward.\n\nThis summit will unite 200+ gene therapy and neurology leader
 s with a program designed to cater to everyone from Discovery through to 
 Clinical Development\; this is your only opportunity for a cover-to-cover
  discussion full of need-to-know and practical insights.\n\nNow that the 
 neurological gene therapy field has been given a renewed sense of directi
 on\, this is the opportunity for the community to capitalize on the start
  of a new wave of innovation and optimize the potential for gene therapie
 s targeting neurological disorders.\n\nTime: 9:00 am - 4:00 pm\n
DTEND:20231109T160000
DTSTAMP:20260512T231934Z
DTSTART:20231106T090000
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, Massachusetts\, 0211
 6\,
SEQUENCE:0
SUMMARY:Despite a challenging 2022 for Gene Therapy developers targeting t
 he CNS\, the recent approvals of Skysona by bluebird bio and Upstaza by P
 TC Therap...
UID:6a00f6b1-fd4c-42f0-9d32-c991e8402462
END:VEVENT
END:VCALENDAR